Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

β-Lapachone Antagonizes Ubiquitin-Specific Protease 18 Activity to Elicit Anti-Neoplastic Effects

ABSTRACT: The deubiquitinase (DUB) Ubiquitin-Specific Protease 18 (USP18) is as an antineoplastic target. USP18 inhibitors are needed. To address this unmet need, we engineered an enzymatically active human recombinant USP18 protein for high-throughput screening. This found β-lapachone was an inhibitor of USP18-ISG15 activity. Independent β-Lapachone treatments of murine and human lung cancer cell lines statistically-significantly reduced proliferation and increased apoptosis. Gain of USP18 expression opposed these effects. β-Lapachone treatments statistically- significantly repressed growth of H1299 human lung cancer xenografts in athymic mice and also in syngeneic mice transplanted with murine 344SQ lung cancers. β-Lapachone increased reactive oxygen species (ROS) but antineoplastic effects proceeded at concentrations having little ROS production. ROS scavenger treatments did not rescue anti-cancer effects, indicating an ROS-independent anti-neoplastic mechanism was engaged. To identify this an Interferon-Stimulated Response Element (ISRE) reporter assay was used. β-Lapachone treatment activated this reporter activity as expected for a USP18 inhibitor. β-Lapachone treatment increased global ISG15 conjugation. Proteomic analysis and immunoprecipitation assays revealed known and new ISG15ylated proteins. RNA sequencing of parental lung cancer cells engineered with or without gain of USP18 expression found differentially expressed genes and pathways after β-lapachone treatments. Taken together, β-lapachone is a novel USP18 inhibitor and cancer biology tool.

ORGANISM(S): Homo sapiens

PROVIDER: GSE318135 | GEO | 2026/02/04

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Chemical tools to define and manipulate interferon-induced Ubl protease USP18

Project description:Ubiquitin-specific protease 18 (USP18) is a multifunctional cysteine protease primarily responsible for deconjugating interferon-induced ubiquitin-like (Ubl) modifier ISG15 from protein substrates. Here, we report the design and synthesis of activity-based probes (ABPs) capable of selectively detecting USP18 activity over other ISG15 cross-reactive Ubl proteases by incorporating unnatural amino acids into the C-terminal tail of ISG15. Combining with a ubiquitin-based DUB ABP, the selective USP18 ABP is employed in a chemoprotemic platform to identify and assess inhibitors of DUBs including USP18. We further demonstrate that USP18 ABPs can be utilized to profile differential activities of USP18 in lung cancer cell lines, providing a strategy that will help define the activity-related landscape of USP18 in different disease states and unravel important (de)ISGylation-dependent biological processes.

2024-03-26 | MSV000094406 | MassIVE

Extracellular ISG15 drives severe respiratory pathology during viral infection

Project description:Cytokine storm during respiratory viral infection is an indicator of disease severity and poor prognosis. Type 1 interferon (IFN-I) production and signaling have been reported to be causal in cytokine storm associated pathology in several respiratory viral infections, however, the mechanisms by which IFN-I promotes disease pathogenesis remain poorly understood. We report using Usp18-deficient, USP18 enzymatic inactive and Isg15-deficient mouse models that lack of deISGylation during persistent viral infection leads to severe immune pathology characterized by hematological disruptions, cytokine amplification, lung vascular leakage and death. Transcriptional studies of immune cells from mice bearing the enzymatic inactive version of USP18 (Usp18C61A) revealed a neutrophil influx in the lung of these animals during infection, associated with increased immature neutrophil content. These neutrophil differentiation changes were dependent on ISG15 as deletion of Isg15 from C61A animals reversed the accumulation of immature neutrophils. Importantly, neutrophil depletion reversed morbidity and mortality in Usp18C61A mice. In summary, we reveal Usp18 enzymatic function is crucial for regulating extracellular release of ISG15 which are accompanied by altered neutrophil differentiation, cytokine amplification and mortality following persistent viral infection.

2025-04-23 | GSE148329 | GEO

A co-opted ISG15-USP18 binding mechanism normally reserved for deISGylation controls type I IFN signalling

Project description:Type I interferon (IFN) signalling induces the expression of several hundred IFN-stimulated genes (ISGs) that provide an unfavourable environment for viral replication. To prevent an overexuberant response and autoinflammatory disease, IFN signalling requires tight control. One critical regulator is the ubiquitin-like protein ISG15, evidenced by autoinflammatory disease in patients with inherited ISG15 deficiencies. Current models suggest that ISG15 stabilises USP18, a well-established negative regulator of IFN signalling. USP18 also functions as an ISG15-specific peptidase that cleaves ISG15 from ISGylated proteins; however, USP18’s catalytic activity is dispensable for controlling IFN signalling. Here, we show that the ISG15-dependent stabilisation of USP18 involves transient hydrophobic interactions. Nonetheless, while USP18 stabilisation is necessary, it is not sufficient for regulation of IFN signalling. USP18 requires non-covalent interactions with the ISG15 C-terminal diGlycine motif to promote its regulatory function. This trait may have been acquired in humans through co-option of a binding mechanism normally reserved for deISGylation, identifying an unexpected new function for human ISG15.

2025-03-07 | PXD051575 | Pride

Deep analysis of the USP18-dependent ISGylome and proteome unveils important roles for USP18 in tumour cell antigenicity and radiosensitivity

Project description:The deubiquitylating enzyme USP18 is a major negative regulator of the interferon (IFN) signalling cascade. IFN pathways contribute to resistance to conventional chemotherapy, radiotherapy, and immunotherapy and are often upregulated in certain tumours, including breast, lung, and colon tumours. USP18 is the predominant human protease that cleaves interferon-stimulated gene ISG15, a ubiquitin-like protein tightly regulated in the context of innate immunity, from its modified substrate proteins in vivo. In this study, using advanced proteomic techniques, we have expanded the USP18-dependent ISGylome and proteome in a chronic myeloid leukaemia (CML)-derived cell line (HAP1) treated with type I IFN. Novel ISGylation targets were characterised that modulate the sensing of innate ligands, antigen presentation and secretion of cytokines. Consequently, CML USP18-deficient cells are more antigenic, driving increased activation of cytotoxic T lymphocytes (CTLs) and are more susceptible to irradiation. Our results suggest USP18 as a pharmacological target in cancer immunotherapy and radiotherapy.

2022-02-15 | PXD018299 | Pride

USP18 interactor and PTM mass spectrometry

Project description:The ubiquitin-like protein ISG15 is activated in response to type 1 interferons and its conjugation to proteins regulates the response to bacterial and viral infection. Its subsequent deconjugation, by a single human enzyme, USP18, critically controls interferon signaling and the defense against pathogens. Accordingly, human mutations in USP18 give rise to interferonopathies. However, the molecular determinants underlying USP18 specificity for ISG15 remain elusive. We have identified key mechanisms that underlie the specificity of USP18 towards ISG15, by taking advantage of USP18’s largely unstudied human paralog USP41. Remarkably, we show that USP41 completely lacks the ability to perform deISGylation, despite possessing a catalytic domain that is 97% identical to that of USP18. Using a variety of in vitro and in vivo assays, we performed a comparative analysis to reveal new mechanisms of deISGylation. We define a short, conserved stretch of amino acids, that we term the TAIL motif, as well as a conserved leucine residue in the catalytic domain, which are necessary for deISGylation. Structural analysis revealed that these residues contact ISG15 and are conserved between USP18 and PLpro from SARS-Cov2, underlining their importance in ISG15 specification. Finally, while little is known about USP41, we found that it can bind and negatively regulate FAT10, a poorly studied Ubl which is also involved in the interferon response. While a FAT10 deconjugating enzyme has long been postulated, no such enzyme has ever been described.

2025-07-14 | PXD058618 | Pride

Upregulation of USP18-ISG15 axis associates with protective immune responses and limited histopathology during SARS-CoV2 infection of the human lung

Project description:Investigating the intra-lung human immune responses to SARS-CoV-2, and how immune signatures temporally correlate to distinct histopathological manifestations of disease in the human lung, is not possible in human patients. While current non-human primate and rodent models have proven instrumental for evaluating COVID-19 treatments and vaccines, their non-human nature precludes faithful recapitulation of fundamental host-pathogen interactions and immunopathogenesis, particularly those governing severe COVID-19 disease. Here, using different mouse models engrafted with human lung tissues and human immune hematopoietic cells, we provide a unique picture of how differential human hematopoietic reconstitution, and immune signatures upon infection, correlate with distinct histopathology during SARS-CoV-2 infection. To do so, we engrafted pairs of human fetal lung xenografts (fLX) harboring lung-resident hematopoietic lineages into immunodeficient NRG mice (NRG-L), or into NRG-Flk2-/-Flt3LG mice co-engrafted with components of a human immune system (HIS-NRGF-L). Strikingly, while SARS-CoV-2 inoculation of NRG-L mice resulted in productive infection and extensive histopathological features typically observed in the lungs of severe COVID-19 patients, HIS-NRGF-L were able to rapidly control infection while preserving tissue integrity. Distinct histopathological outcomes were governed by differential proteomics and phospho-proteomics signatures and underscored the USP18-ISG15 pathway as a top immunomodulatory pathway defining effective control of viral replication and maintenance of tissue integrity in human lung tissue during SARS-CoV-2 infection. Our work highlights fLX-engrafted mice as a powerful platform to investigate the molecular basis that drives effective immune control of SARS-CoV-2, and open avenues for the development of innovative immunotherapies targeting the USP18-ISG15 pathway to alleviate severe COVID-19.

2022-04-14 | PXD025851 | Pride

Single-cell transcriptomic analysis of tumor-infiltrated immune cells from myeloid-specific Usp18 knockout mice

Project description:Ubiquitin specific peptidase 18 (USP18) inhibits type I interferon response and mediates ISG15-deconjugation. Here, we examined the role of USP18 in myeloid-linage cells in tumor development. B16F10 melanoma grown in control or myeloid-specific Usp18 knockout mice were analyzed. Single-cell transcriptomic analysis revealed that the profile of tumor-infiltrated immune cells were altered with Usp18 deletion. We observed that increase in M1-polarized macrophages and decrease in myeloid-derived suppressor cells, resulting enhanced anti-tumor microenvironment in Usp18 conditional knockout mice.

2024-02-14 | GSE173705 | GEO

MDA-MB-231 MS analysis of ISGylome, GDI2 interactome and total proteome changes in different ISGylation models

Project description:Analysis of ISG15 conjugation (Isgylation)role as driver of poor prognosis in non HER2+ breast cancer tumours. The project includes an analysis of total proteome and ISGylome characterization of MDA-MB-231 cells, wild-type or knock-out for the ISGyltaion associated genes, ISG15, UBE2L6 and USP18. Additionally interactome analysis of the ISGylation target GDI2 was perfored in the same lines.

2021-11-03 | PXD025753 | Pride

Expression data from WT and ISG15 KO HaCaT cells stimulated with interferon-a and treated with combination treatment of Ruxolitinib, TGFb and Doxycycline

Project description:Analysis of gene expression in WT and ISG15 KO HaCaT cells, stimulated with IFNa and treated with ruxolitinib (RUX), transforming growth factor beta (TGFb) and doxycycline (DOXY) to investigate the effects of treatments on transcriptional response in the cells.

2022-03-17 | GSE186391 | GEO

Lestaurtinib inhibits therapy resistant ovarian cancer

Project description:Ovarian cancer is the deadliest gynecological malignancy, owing to its late-stage diagnosis and high rates of recurrence and resistance following standard-of-care treatment, highlighting the need for novel treatment approaches. Through an unbiased drug screen, we identified the kinase inhibitor, lestaurtinib, as a potent antineoplastic agent for chemotherapy- and PARP-inhibitor (PARPi)-sensitive and -resistant ovarian cancer cells and patient derived xenografts (PDXs). RNA-sequencing revealed that lestaurtinib potently suppressed JAK/STAT signaling and lestaurtinib efficacy was shown to be directly related to JAK/STAT pathway activity in cell lines and PDX models. Most ovarian cancer cells exhibited constitutive JAK/STAT pathway activation and genetic loss of STAT1 and STAT3 resulted in growth inhibition. Lestaurtinib also displayed synergy when combined with cisplatin and olaparib, including in a model of PARPi resistance. In contrast, the most well-known JAK/STAT inhibitor, ruxolitinib, lacked antineoplastic activity against all ovarian cancer cell lines and PDX models tested. This divergent behavior was reflected in the ability of lestaurtinib to block both Y701/705 and S727 phosphorylation of STAT1 and STAT3, whereas ruxolitinib failed to block S727. Consistent with these findings, lestaurtinib additionally inhibited the serine/threonine kinases, JNK and ERK, leading to more complete suppression of STAT phosphorylation. Concordantly, combinatorial treatment with ruxolitinib and a JNK or ERK inhibitor resulted in synergistic antineoplastic effects at dose levels where the single agents were ineffective. Taken together, these findings indicate that lestaurtinib, and other treatments that converge on JAK/STAT signaling, are worthy of further pre-clinical and clinical exploration for the treatment of highly aggressive and advanced forms of ovarian cancer.

2025-06-30 | GSE291796 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data